|Bid||85.03 x 900|
|Ask||95.00 x 800|
|Day's Range||84.93 - 86.13|
|52 Week Range||69.36 - 94.85|
|Beta (3Y Monthly)||1.20|
|PE Ratio (TTM)||19.78|
|Earnings Date||Aug 1, 2019|
|Forward Dividend & Yield||1.60 (1.88%)|
|1y Target Est||89.00|
We are upbeat about solid contributions from Boston Scientific's (BSX) Cardiovascular business group, which comprises Interventional Cardiology and Peripheral Interventions.
Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine and an upbeat second quarter 2019 view are likely to fuel Stryker's (SYK) Q2 earnings. However, forex might be a woe.
Intel's (INTC) launch of FPGA SDK and Xeon Scalable will drive top-line growth. However, decline in NAND flash pricing, lower platform revenues & expenses related to 4G modem ramp remains a headwind.
Solid global demand, substantial impact from the electron microscopy business and robust volume growth and productivity are likely to favor Thermo Fisher's (TMO) analytical instruments revenues.
Probable revenue growth in APAC and EMEA regions and higher Oncology revenues are likely to aid Varian Medical (VAR) in Q3 earnings. However, contraction in margins might be a dampener.
Cadence Design (CDNS) gains from strong adoption of it's digital and signoff, custom and analog, IP solutions and expanding customer base.
Newly released federal data shows how drugmakers and distributors increased shipments of opioid painkillers across the U.S. as the nation’s addiction crisis accelerated from 2006 to 2012.
Zacks.com featured highlights include: Oracle, AngloGold Ashanti, AmerisourceBergen, Ford Motor and CACI International
Skyworks (SWKS) is expected to get hurt by softness in Chinese market. Moreover, unit decline across mobile business is likely to impact the third-quarter results.
AmerisourceBergen (ABC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Top-line growth and better-than-expected segmental performance are likely to aid McKesson (MCK) in Q1. However, rise in adjusted operating expenses is likely to be a dampener.